Disruptive Capital

What is Disruptive Capital?

Disruptive Capital is a venture capital firm headquartered in the UK, specializing in seed investments across a wide range of sectors and stages. They focus on sourcing and managing opportunistic investments by leveraging market dislocations and complex opportunities.

Their investment thesis is centered on creating value with a track record of delivering a 33% Internal Rate of Return (IRR) on all realised investments over a period of 27 years.

Disruptive Capital invests in an extensive portfolio that includes sectors such as green energy, bioresearch, regulatory technologies, pension insurance, technology infrastructure, paperless global trade, health destinations, viral vectors manufacturing for cell and gene therapies, financial services, historic hotels, digital health platforms, and integrated energy transmission platforms.

Notable ventures include Atlantic SuperConnection, which aims to develop a 1,600km subsea cable to import 1.8 GW of geothermal and hydro-electric power from Iceland to the UK, and Brooklyn ImmunoTherapeutics, a company focused on developing new immunotherapies for cancer. They also have investments in REG Technologies, Pension Insurance Corporation, Telent, essDocs, Ptarmigan Health Destinations, ViroCell Biologics, Disruptive Capital Acquisitions Company Ltd, The Kurhaus Arolla, Careful Systems, and Global Interconnection Group.

Beyond direct investments, Disruptive Capital offers insights on their portfolio companies' advancements and sector-specific news, demonstrating a commitment not only to financial backing but also to strategic involvement in their investments' growth and success.